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ABSTRACT: A Cytokeratin 8 (K8)/Green Fluorescent Protein (GFP) fusion construct was created to better under-
stand the behavior of K8 within cancer cells. This intermediate filament (IF) protein is a member of the cytoskeletal 
gene family, along with actin and tubulin. IFs are normally expressed in a tissue-specific and differentiation-dependent 
manner, in which their role is more supportive than essential to the cell. Such roles include rigidity of cellular shape, 
protein trafficking, cellular locomotion, and cell-signaling platforms. K8 mutation, over-expression, and aberrant post 
translational modifications have been observed in various carcinoma cell lines to be the cause of several phenotypes, 
including apoptosis inhibition, drug resistance, transformation, Mallory-Denk body formation, localization at the 
plasma membrane, and secretion of the protein. 
To study these abnormal phenotypes, the K8 gene was isolated and inserted into the GFP over expression vector. 
Transfecting this vector into HeLa cells allowed for the study of K8 within a well-defined cervical cancer cell line. This 
study was intended to provide answers to K8’s localization at the plasma membrane in carcinoma cell models while 
avoiding criticisms to previous immunohistochemical localization studies. A cellular model of K8 processing that 
exhibits established phenotypes found in the literature was thus created and has the potential to address several para-
mount questions related to K8’s role in supporting the development and progression of cancer. It could also be utilized 
as an assay for the discovery of K8 filament formation inhibitors, which may prove useful in combination with current 
chemotherapeutics. The model could also be used to provide weight to diagnostics, such as the CAncer REcognition 
test, which utilizes antibodies against K8 as biomarkers for malignancy via an Enzyme-Link ImmunoSorbent Assay.
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INTRODUCTION 
Early cancer detection and disease monitoring methods 
are crucial to patient survival. When a tumor is still in its 
tissue of origin, the disease is far more manageable and 
treatments produce more optimistic prognoses; for this 
reason, it is paramount to identify the presence of cancer 
cells as early as possible. Unfortunately, modern medicine 
is strongly focused on treatment and less on prevention. 
Only when both are utilized in an efficient and timely 
manner can future generations hope to see a decline in 
the morbidity and mortality caused by this disease. 
Most cancers arise through genetic mutations in growth 
regulatory circuits resulting in uncontrolled proliferation 
or defects in programmed cell death pathways.  While 
these mutations can be the cause of the disease, they can 
also lead to its detection and treatment. Subtle yet 
significant surface alterations, or tumor markers, can be 
found on carcinoma cells which differentiate them from 
the surrounding normal tissue. Having the ability to 
differentiate normal cells from those which have 
transformed is a rational foundation for the development 
of a diagnostic test for the presence of the disease.
One such alteration can be found in cytokeratin 8’s (K8) 
aberrant localization in several carcinoma cell lines. K8 is 
a cytosolic protein and a member of the Intermediate 
Filament (IF) family. IFs, together with actin and tubulin, 
define the cytoskeleton of eukaryotic cells, with IFs 
representing the largest of the cytoskeletal gene families. 
IFs are expressed in a tissue-specific and differentiation-
dependent manner, and they serve various purposes, 
including rigidity of cellular shape, intracellular 
organization of proteins, transport, locomotion of the 
cell, scaffolding functions, and cell signaling platforms 
(Strnad et al. 2008). Since these proteins assist in such a 
variety of ways, they frequently interact with numerous 
kinases, adaptor, and apoptotic proteins. 
Keratin nomenclature breaks down the group into two 
sub-types based on their pH: acidic keratins known as 
type I and basic keratins known as type II. Type I and 
type II keratins bind with each other to create 
heteropolymer filaments. Specific keratin pairs are 
preferentially expressed in individual cell types (Strnad et 
al. 2008); one commonly expressed type I/type II pair of 
interest is K8 and K18. This keratin pair is observed in 
almost all single-layered epithelia cells (Strnad et al. 
2008).
IF proteins’ supportive rather than essential intracellular 
roles allow for mutations to go unchecked and lead to 
cellular characteristics such as chemotherapeutic 
resistance (Lau & Chiu 2007; Wang et al. 2008; Liu et al. 
2008), transformation (Raul et al. 2004; Gilbert, 
Loranger, Daigle, & Marceau 2001; Gires et al. 2006), 
and an aggregation of the K8 into inclusion bodies 
known as Mallory-Denk Body formations (Gires et al. 
2006; Ku & Omary 2000). So how can we use the 
mutation of K8 to our advantage in the detection of 
cancer?  
Previous studies discovered a high titer of IgM antibodies 
within cancer patients which bound specifically to an 
epitope found on K8 named LT-11. These studies led to 
the initial development of an Enzyme Linked 
ImmunoSorbent Assay (ELISA) diagnostic termed the 
CAncer REcognition (CARE) test (Thornthwaite et al. 
2004). The assay utilizes the Anti-K8 antibodies found 
selectively in cancer patient serum as a sensor for tumor 
presence; but, in order to present itself to the immune 
system, intracellular K8 must somehow be localizing at 
the cell surface or releasing itself from the cell due to lysis 
or secretion. Investigations exploring how K8 was being 
presented to the immune system, and why it was 
considered foreign only in the case of tumor cells, needed 
to be carried out.  
To better understand this phenomenon a model system 
was generated to study the localization of K8 within a 
cancer cell. Localization studies had been previously 
carried out (Gires et al. 2005), but with substantial 
criticisms. In said study, “non permeabilized” cells were 
subjected to staining using anti LT-11 antibodies and 
imaged via fluorescence microscopy. Results showed a 
strong signal at the plasma membrane, signifying the 
presence of K8 at the cell’s surface. Unfortunately, the 
study’s use of potentially membrane destabilizing 
immunostaining techniques could have generated false 
signals of the protein’s presence at the cell surface. By 
utilizing a green fluorescent protein (GFP) tag bound to 
K8, our new model avoided the need for immunostaining 
and allowed us to image the protein directly. It also 
created a platform which could be utilized to explore 
new questions regarding the aberrant behavior of K8.  
It is of great importance to develop a K8 over-expression 
cellular model that exhibits the same phenotypes as the 
various carcinomas documented in the literature. Our 
study is thus the creation of a model system in which 
K8’s biochemical characteristics within cancer can be 
4.2. 20–30
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observed. These studies aimed to empower potential 
diagnostics utilizing K8 and develop an assay which 
could be used for the discovery of novel drug inhibitors 
of K8/K18 formation.  
METHODS AND MATERIALS 
Target Gene Isolation
The K8 gene was generated utilizing a colon cancer 
(HCT-116) cell line cDNA library, created in our 
laboratory by graduate student Jose Salvatico. First K8-F 
(5’- GGT TCT CCG CTC CTT CTA GG -3’) and 
K8-R (5’- CTC CTG TTC CCA GTG CTA CC -3’) 
primers containing no restriction enzyme (R.E.) sites 
were used in a polymerase chain reaction (PCR) to 
generate the K8 gene. PCR profile was as follows: 30 
cycles (95 °C, 15 sec, 51-61 °C gradient, 30 sec, 68 °C, 1 
min 30 sec). All PCR reactions were carried out using 
Eppendorf ’s Master Cycler Gradient thermocycler. The 
elongation time needed for the K8 gene was calculated 
using the following ratio: approximately 1 Kb per 60 sec 
(K8 = 1.4 Kb ≈ 1 min 30 sec). Annealing temperatures 
ranging from 51 to 63 degrees were used to test for the 
primer’s optimum conditions. PCR product yields were 
determined by loading samples onto a 1% agrose gel, 
separating samples via electrophoresis and staining the 
gel with Ethidium bromide (EtBr). The greatest and 
purest yield (brightest signal band) was found at 54.3 °C. 
The PCR product taken from this tube was purified via 
the QIAquick PCR purification kit, provided by 
QIAGEN (Valencia, CA). 
Next, custom K8 inserts were created for both the 
EGFP-C and EGFP-N plasmids from BD Biosciences 
(San Jose, CA). The K8-N insert was generated using 
CK8R1-NF (5’- A TAT GAA TTC GCC ACC ATG 
TCC ATC AGG GTG ACC CAG -3’) and Krt8N-
BamH1-Rev (5’- T ATT GGA TCC AA CTT GGG 
CAG GAC GTC AGA -3’) primers. The K8-C insert 
was generated using Krt8C-EcoR1-Rev (5’- T AAT 
GAA TTC A ATG TCC ATC AGG GTG ACC 
CAG-3’) and ck8BH1-CR (5’- T TAT GGA TCA CTT 
GGG CAG GAC GTC AGA AAG TGA -3’). These 
primers were placed in separate tubes with the K8 
template DNA, and PCR was carried out with the 
following profile: (95 °C, 15 sec, 54.3 °C, 30 sec, 68 °C, 1 
min 30 sec). PCR product yields were then observed on 
a 1% agrose gel. The PCR products were then purified via 
QIAquick PCR purification. Both K8-C and K8-N 
inserts were then R.E. digested using EcoR1 and BamH1 
in React 3 buffer provided by Invitrogen (Carlsbad, CA) 
at 37 °C for 1 ½ hr. 
Digested samples were then purified via Phenol/
Chloroform and Ethanol (P/C/Ethanol) precipitation. 
Each DNA sample was adjusted to 110 μl total volume 
by adding de-ionized H2O (dH2O). This process was 
followed by the addition of 30 μl of Phenol/Chloroform. 
The samples were centrifuged at 14,000 rpm for 5 min, 
the top 100 μl of solution were transferred to a new tube 
and the following were added: 10 μl 3 M NaOAC, 1 μl 
glycogen and 300 μl 100% ethanol kept at -20 °C. The 
tubes were then incubated at -80 °C for 15 min. DNA 
was pelleted by centrifugation at 13,000 rpm for 15 min 
at 4 °C and supernatant was removed. The pellet was 
then resuspended in 100 μl of 70% ethanol kept at -20 
°C and re-pelleted at 14,000 rpm for 5 min at 4 °C. 
Supernatant was removed and pellet was allowed to dry 
at room temperature. DNA was finally resuspended in 
15 μl of dH2O.
Ligation 
K8-C and K8-N were inserted into either EGFP-N or 
EGFP-C plasmids to create K8/GFP-N and GFP/K8-
C. First the DNA concentrations of both the plasmids 
and inserts were measured at 260 nm by loading 2 μl of 
sample with 98 μl of dH2O using TECAN’s GENios 96 
well plate reader (Männedorf, Switzerland). Then 
EGFP-C was mixed with K8-C and EGFP-N was 
mixed with K8-N in the following ratios (Insert to 
Plasmid): 6:1 and 12:1. Ligation was carried out at room 
temp (approximately 22.5 °C) for 1 hour. Ligated 
products were then purified via P/C/Ethanol 
Precipitation and re-suspended in 20 μl of dH2O 
(plasmids were maintained at a high concentration to 
increase transformation efficacy).
Transformation 
K8/GFP-N and GFP/K8-C were transformed into XL-
Gold Escherichia coli Ultra Competent cells provided by 
Stratagene (La Jolla, CA) via heat shock. XL-Gold E.coli 
cells were first thawed on ice and treated with 
β-mercaptoethanol. Both the 6:1 and 12:1 ligation 
products were mixed together, placed with cells and 
allowed to set for 30 min on ice. Cells were then placed 
in a dry bath at 42 °C for 30 sec then allowed to grow in 
Luria-Bertani (LB) media for 45 min in an incubator 
shaker at 37 °C. Cells were pelleted, plated on Kanamycin 
(Kan) selective plates and incubated over-night. Colonies 
were selected and placed in 3 mL of LB (Kan) media for 
15 hrs in a shaker incubator at 37 °C.             
4.2. 20–30
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Screening of Colonies 
Plasmids from cultured cells were harvested via QIAprep 
Spin Mini Prep Kit, provided by QIAGEN. The isolated 
plasmids were digested with EcoR1 and BamH1 at 
37 °C and analyzed on a 1% agrose gel to confirm 
insertions. Positive clones were found for GFP/K8-C, 
while all of the K8/GFP-N plasmids were negative for 
the K8 insert. The process of ligation and the 
aforementioned procedures were repeated for the K8/
GFP-N plasmid using Max Efficiency® DH5-α-T1 
competent E. coli cells (Invitrogen). 
Plasmid Sequencing 
Positive clones were chosen and grown in 3 mL of LB 
(Kan) media. These cultures were harvested and plasmid 
DNA concentrations were then measured at 260 nm 
with a 280 nm purity reference. GFP/K8-C and K8/
GFP-N were sent to GENEWIZ (South Plainfield, NJ) 
for sequencing. Results came back 99% homologous to 
K8’s sequence found in the National Center for 
Biotechnology Information database with one silent 
mutation. 
Verification of Expression 
Both GFP/K8-C and K8/GFP-N plasmids were 
transfected into HeLa (Cervical) and MDA-MB-231 
(Breast Cancer) cell lines for the purpose of Western blot 
confirmation of K8/GFP fusion protein expression. 
First, both cell lines were grown to 95% confluency on a 
6 well plate. Next, 1 μg and 2 μg of each plasmid were 
added to separate tubes containing 250 μl of OPTI-
MEMI media (1 μg of a blank DNA was added to the 1 
μg plasmid tubes to keep DNA concentrations constant). 
A 8 μl volume of Lipofectamine™ 2000 (Invitrogen) was 
mixed with 250 μl of OPTI-MEMI media for each 
transfection well, then added to the DNA/OPTI-
MEMI suspensions and incubated at room temperature 
for 20 min. Growth media was removed from each well 
and 500 μl of the Lipofectamine/plasmid mixture was 
added. HeLa cells were then given 1 ml of serum free 
RPMI, while MDA-MB-231 cells were given 10% FBS 
DMEM media. Plates were gently rocked to spread 
plasmid evenly and placed in the culture incubator for 24 
hrs; 1 ml of 20% RPMI was given to the HeLa cell 
cultures after 5 hrs. 
Media was removed from all transfection wells, then cells 
were trypsinized and pelleted in a microcentrifuge at 
room temperature. Cells were then washed with 1ml of 
phosphate buffered saline (PBS), and re-suspended in 
50 μl of 1x radio-immunoprecipitation assay buffer 
containing ethylenediaminetetraacetate(EDTA)-free 
protease inhibitor cocktail (Roche Diagnostics). Tubes 
were placed on ice for 30 min then centrifuged at 14,000 
rpm for 10 min at 4°C. The supernatant (cytosolic 
fraction) was transferred to a new tube and the protein 
concentrations were measured via Bradford assay. 
Protein samples were suspended in 5x SDS loading dye 
containing: 2.0 ml 1 M Tris-HCl pH 6.8, 0.8 g SDS, 4.0 
ml 100% glycerol, 0.4 ml 14.7 M β-mercaptoethanol, 1.0 
ml 0.5 M EDTA and 8 mg bromophenol Blue. Samples 
were heated at 95 °C for 5 min and approximately 10 μg 
were loaded onto a .75 mm 10% polyacrylamide gel. 
Electrophoresis was carried out at 80 volts for 60 min 
then 150 volts for 25 min. Proteins were then transferred 
to a nitrocellulose membrane at 100 volts for 90 min. The 
membrane was then probed for the GFP and Actin (to 
act as a loading control) with the following antibodies 
(and their concentrations): Primary antibodies- (1:1,000 
mouse α-GFP) and (1:10,000 Rabbit α-actin), Secondary 
antibodies- (1:1,000 Goat α-rabbit IgG, Horseradish 
Peroxidase(HRP)-conjugated) and (1:1,000 Goat 
α-mouse IgG, HRP-conjugated). Antibodies came from 
the following sources: Mouse α-GFP and Goat  α-mouse 
IgG (Santa Cruz Biotechnology), Rabbit α-actin 
(Sigma) and Goat α-rabbit IgG, HRP-conjugated 
(Pierce). Remaining samples were stored at -80 °C. 
Twelve days later western blot procedures were repeated, 
utilizing those samples taken from cells transfected with 
2 μg of plasmid. 
Slide Preparations 
After Western blot analysis showed the presence of the 
fusion protein, confocal imaging of K8/GFP was carried 
out. Plasmids were transfected into the HeLa cell line, 
which was grown on glass cover slips. The transfected 
cells were prepared and sealed onto microscope slides 
and then imaged by confocal microscopy. 
HeLa cell cultures were grown to 40% confluency on 
glass coverslips. Following this, 1 μg of GFP/K8-C or 
K8/GFP-N plasmids were transfected into separate 
HeLa cultures (see Verification of Expression Product for 
procedure). The cover slips were transferred to a new 12 
well plate, 2 ml of 2% Paraformaldehyde were added to 
each well and allowed to incubate at room temperature 
for 15 min. Wells were washed by decanting the 
supernatant, adding 3 ml of PBS, incubating for 2 min 
and removing the PBS; this process was done twice. 
To-Pro 3 Iodide (1:5000 dilution) in 1 ml PBS was 
4.2. 20–30
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added to each well and incubated in darkness for 30 min 
to counter-stain DNA. The samples were kept in darkness 
for the rest of the preparations. Wells were washed and 
cover slips were mounted onto microscope slides using 
10 μl of Vectashield™ mounting solution minus DAPI 
(Plasmid). The cover slips were sealed using clear nail 
polish, and dried for 10 min. Slides were then stored at 
-20 °C until imaged. Imaging was carried out using the 
ZEISS Axiovert 100M confocal microscope and its 
associated software. 
To evaluate K8/GFP localization at the plasma 
membrane, Z-stacking was performed. This technique 
utilizes the confocal microscope’s ability to block out of 
focus light from the detector, therefore accurately 
depicting a single focal plane. Several focal planes, from 
the bottom of the cell to the top, are then captured and 
analyzed. These planes can then be processed and placed 
on top of each other, forming a three-dimensional image 
which provides better cellular structure detail. 
RESULTS AND DISCUSSION
The K8 gene was cloned from a HCT-116 cell line 
cDNA library using PCR. This was carried out at varying 
annealing temperatures to find optimal conditions (high 
product purity and quantity). Figure 1 shows an optimal 
product at 54.3 °C annealing temperature. This product 
was then inserted into both GFP-C and GFP-N vectors, 
and sent in for sequencing.
4.2. 20–30
FIGURE 1: PCR OPTIMIZATION
PCR products created from addition of K8-F and K8-R primers with 
HCT-116 cDNA library, carried out at annealing temperatures from 
51 to 63°C. Samples were loaded onto a 1% argose gel and run at 
75volts for 60min. K8 sequence is 1.4Kb in length.
FIGURE 2: SEQUENCING RESULTS FOR THE                                    
GENERATED K8 INSERT VERSUS THE K8 GENE 
FOUND IN THE NCBI DATABASE
One silent mutation, illustrated by above codon translation, was found 
in both K8 inserts (K8-C and K8-N) making them 99% homologous 
with documented K8 sequence.  
Western blot analysis showed a distinct difference in 
the post translational modification of K8/GFP-N and 
GFP/K8-C in the MDA-MB-231 cell line (Figure 3). 
The results show that these cells may be able to process 
K8/GFP-N more efficiently than GFP/K8-C, since K8/
GFP-N samples showed little to no signal around the 
80.5 kDa region. The K8/GFP was undoubtedly ex-
pressed in these cells since the fusion construct generates 
a single polypeptide and immunoreactivity was observed 
at approximately 27 kDa, the weight of GFP. Thus, the 
K8/GFP protein was expressed, but the K8 portion was 
preferentially lost due to degradation or secretion.      
The results also show a difference in the post translation-
al modification of the fusion protein in MDA-MB-231 
cells compared to the HeLa. MDA-MB-231 cells may 
be able to proteolytically process K8 more efficiently 
than the HeLa cells.  If HeLa had an intrinsically higher 
level of K18 expression, for example, this would facili-
tate the protection of the K8/GFP protein by promoting 
filament formation when the K8/GFP and K18 concen-
trations were approximately equal. It is well established 
in the literature that the formation of K8/K18 filaments 
helps to protect the two proteins from degradation (Gil-
bert, Loranger, Daigle, & Marceau 2001).
Further observations showed the presence of multiple 
K8/GFP fragments exclusively within HeLa cells 
transfected with the GFP/K8-C plasmid; such distinct 
fractions were not observed in the same concentration of 
protein sample taken from the K8/GFP-N transfected 
cells (Figure 4).
Sequencing results confirmed that both vectors contain 
copies of the K8 gene and had one silent mutation at 
nucleotide 680, making them 99% homologous with the 
sequence found in the NCBI database (Figure 2). Once 
these constructs were transfected into the cancer cell 
lines, HeLa and MDA-MB-231, the cytosolic protein 
fractions were analyzed for the presence of the desired 
fusion product.
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FIGURE 3: VERIFICATION OF GFP/K8-C AND K8/GFP- N EXPRESSION IN MDA-MB-231 AND HELIA WESTERN
BLOT UTILIZING α-GFP. 
FIGURE 4: SECONDARY VERIFICATION OF GFP/K8-C AND K8/GFP-N EXPRESSION AND FRAGMENTATION 
Western blot procedures were repeated after samples were frozen for two weeks to confirm previous expression results and GFP/K8-C exclusive 
fragmentation. All results, except for the presence of an Actin band at ~39kDa, were concurrent with the previous experiment. The GFP fusion 
product has a calculated molecular weight of ~80.5kDa. (a) The MDA-MB-231 cell line showed decreased GFP/K8-C presence in lane (4), no 
K8/GFP-N in lane (2) and the presence of an Actin band. (b) The HeLa samples continued to show both the GFP/K8-C and K8/GFP-N products, 
while fragmentation continued to remain exclusive to GFP/K8-C in lane (6). A distinct Actin band was not observable in the HeLa extracts, until 
an extended exposure of the blot was taken. 
Western blots were probed with both α-GFP and α-Actin.The GFP-K8 fusion product has an expected molecular weight of: ~53.5kDa (K8) + 
~27kDa (GFP) - ~80.5kDa. A GFP product which has been cleaved off of K8 at ~27kDa was observed in all the transfected cells, while no Actin 
bands were present at ~39kDa. Cell extracts from those transfected with the GFP plasmid were used as a GFP molecular weight marker. (a) The 
MDA-MB-231 cell line showed a decreased presence of GFP/K8-C compared to HeLa, potentially due to more efficient degradation/secretion of 
the K8 portion of the construct. (b) The HeLa cell line showed relatively high levels of expression for both GFP/K8-C and K8/GFP-N. A distinct 
GFP/K8-C fragmentation was also observed in lanes (8-9), while K8/GFP-N lanes (11-12) displayed little to no fragmentation bands.
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Previous literature supports the concept of extensive K8 
post translational modifications, proteolytic cleavage 
(Ku, Zhou, Toivola & Omary 1999) and the secretion of 
full length K8 as well as its fragments in some forms of 
lung cancer (Yoko et al. 2002). Combining this informa-
tion with the documented localization of K8’s C-termi-
nal epitope LT-11 at the cell surface (Gires et al. 2005) 
allowed for a model to be generated to help address the 
difference in the observed fragmentation (Figure 5). In 
this model, GFP’s position in relation to K8 is important 
in understanding the difference in the  detectable  bands 
prouced. From the literature (Gires et al. 2005; Yoko
et al. 2002) one could hypothesize that K8 is degraded
and those protein fragments closest to the LT-11 epit-
ope end up on the outside of the cell membrane, wheth-
er it be secreted or inserted.  GFP/K8-C encodes for a 
protein with GFP at the N-terminus of K8 (furthest 
away from the LT-11 C-terminus epitope), producing 
fragments which remain in the cytosol that are detect-
able when probing cytosolic fractions with α-GFP. In 
the case of K8/GFP-N, GFP is encoded directly after 
the LT-11 epitope which will facilitate its export out 
of the cytosol, leaving only full length K8 detectable 
within the cell.
FIGURE 5: MODEL PREDICTING CAUSES OF FGP/K8-C'S FRAGMENTATION SIGNAL
The above model shows predicted destinations of cleaved GFP/K8 fragments and detectability of the fragments using α-GFP. Those fragments that 
remain within the cytosol and have intact GFP should theoretically be present on a western blot of a cytosolic fraction (Figures 4 and 5). 
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Confocal imaging was carried out utilizing the HeLa 
cell line due to its relatively increased expression lev-
els compared to the MDA-MB-231 line. These images 
showed distinct IF formations in HeLa cells transfect-
ed with either GFP/K8-C or K8/GFP-N, while those 
transfected with the original GFP plasmid showed a 
ubiquitous signal throughout the cell without any well-
defined pattern (Figure 6). The ability of the fusion 
construct to form IF networks demonstrates that the 
construct is a fully functional K8 protein. Additionally, 
these images showed an IF structure formation within 
the cells transfected with the fusion protein construct, 
while  lacking  the  distinct  signal  at  the  plasma 
membrane one would expect from the Gires study (Gires 
et al. 2005). In Gires’s study, anti-K8 antibodies were 
used to probe for the protein’s presence at the plasma 
membrane of non-permeabilized carcinoma cells. Im-
ages produced in that study showed K8 localization uni-
versally across the entire membrane which created a shell 
outline of the cell. The lack of a well-defined signal at 
the plasma membrane by the K8/GFP protein, while ex-
hibiting a distinct cytoskeleton structure, suggested that 
the extracellular projection of K8 reported by Gires et. 
al. is an artifact of their immunohistochemical procedure 
(Gires et al. 2005). Since K8 is bound to GFP in our 
system, it can be imaged directly, thereby overcoming the 
limitations of the previous study.
FIGURE 6: K8/GFP DISPLAYS INTERMEDIATE FILAMENT FORMATIONS 
HeLa cells were transfected with the above mentioned plasmids and their DNA was stained using To-Pro 3 lodide. Those transfected with only 
GFP showed localization throughout the cell and no structural formation, while cells transfected with either GFP/K8-C K8/GFP-N showed 
cytosolic localization and intermediate filament formation.
4.2. 20–30
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Preliminary immunoprecipitation (IP) studies of me-
dia taken from HeLa cells transfected with both GFP/
K8-C and K8/GFP-N utilizing α-GFP antibodies were 
performed over a 72 hr period, collecting media and 
harvesting cells every 24 hrs (data not shown). Samples 
were run through Western blot procedures after the IP, 
probing with an α-GFP antibody. A protein band im-
munoreactive with α-GFP antibody was observed at the 
anticipated 80.5 kDa mobility of K8/GFP, but no no-
ticeable lower molecular mass fragments were observed. 
It is possible secreted K8/GFP fragment bands may have 
been obscured by the robust signal produced from the 
heavy chain of α-GFP IgG utilized to pull the fusion 
protein out of the media.  
These results provide a strong indication that the pro-
tein produced by these plasmids was in fact K8 fused to 
GFP in a functional conformation. Within the transfect-
ed HeLa cells, a well-defined IF network incorporated 
products from both of the GFP/K8-C and K8/GFP-N 
plasmids. Also, phenotypes such as the secretion of the 
fusion product into the media and the aggregation of 
the product into K8 containing inclusion bodies (data 
not shown) were observed. These findings would lead us 
to conclude that the developed model system correlates 
well with what would be expected from the current K8 
literature, and that K8 may not ubiquitously localize at 
the plasma membrane as once hypothesized (Gires et al. 
2005). 
FUTURE DIRECTIONS FOR THE PROJECT
Future experiments, such as secretion and localization 
studies, will help to provide answers to K8’s role in 
precancerous cell transformation. In order to evaluate 
the model presented in Figure 5, secretory studies 
could be performed on K8/GFP-N expressing HeLa 
cells. First, samples of media taken from these cell 
cultures would be subjected to immunoprecipitation 
utilizing anti-GFP antibodies. Western blot analysis 
would then help to show if partially degraded K8 
bound to GFP was being secreted or released 
preferentially from the K8/GFP-N expressing cells. 
Other secretory studies utilizing GFP and Red 
Fluorescent Protein (RFP) molecular tags could be 
carried out by transfecting a culture of cells with K8/
GFP and mixing them with cells transfected with K8/
RFP. If K8/RFP protein is observed on a cell expressing 
K8/GFP, or K8/GFP protein on a K8/RFP expressing 
cell, the co-localization of the two fluorophores will 
generate a yellow signal. If such a signal were observed, 
one could then conclude that cancer cells have the 
ability to secrete and attach K8 onto neighboring cells 
(Figure 7A). Similar evaluations of K8’s potential to 
stick to the outer membrane surface could be studied 
by purifying the K8/GFP product and adding it at 
varying concentrations to non-transfected cell 
cultures. Those cultures could then be imaged under a 
confocal microscope to check for the presence of the 
fusion protein on the outside of non-permeabilized 
cells.  
Localization studies could also be carried out utilizing 
K8/GFP transfected cells in direct comparison to 
Actin/GFP transfected cells, since actin is a known 
cytosolic protein. Non-permeablized cells could then 
be probed with a primary α-GFP and a red fluorescent 
secondary antibody to better evaluate if the observed 
localization of K8 is an artifact or not (Figure 7B). 
These experiments could exploit the advantages of 
the immunofluorescences approach, while actively 
addressing criticisms to a “leaky membrane.”
Finally, the current model could be utilized as an assay 
for the discovery of K8 filament formation inhibitors. 
Since K8’s role is considered relatively more supportive 
than essential and the deconstruction of its filaments 
have been found to attenuate drug resistance (Lau & 
Chiu 2007; Wang et al. 2008; Liu et al. 2008), alleviate 
aggressive metastatic phenotypes (Raul et al., 2004; 
Gilbert, Loranger, Daigle, & Marceau 2001) and in 
some cases, promote proapoptotic receptors at the cell 
surface (Gilbert, Loranger, Daigle, & Marceau 2001), 
it may be considered as a potential target for cancer 
therapeutics. By adding various potential inhibitors 
and monitoring K8/K18 filament formation under a 
confocal microscope, the model has the potential to 
discover new drugs which may be useful alone or in 
combination with current chemotherapeutics against 
various forms of carcinoma.
By utilizing this model system and beginning 
preclinical trials of the CARE test (Thornthwaite et 
al. 2004), K8’s true potential as a tumor marker can be 
elucidated. One day, such a diagnostic could be used to 
screen large numbers of patients for a variety of 
cancers during routine blood work in order to catch 
the disease when it is at a more manageable stage. 
Early cancer detection will enable old and new 
treatments alike to become far more effective, and 
allow such procedures to produce far more optimistic 
prognoses.   
4.2. 20–30
9
Leventhal: Characterization of Cytokeratin 8 in Cancer
Published by STARS, 2009
THE UNIVERSITY OF CENTRAL FLORIDA
UNDERGRADUATE RESEARCH JOURNAL
29www.URJ.ucf.edu
FIGURE 7: FUTURE SECRETION AND LOCALIZATION STUDIES 
A K8/GFP (green) and K8/RFP (red) secretion onto neighboring cells and resulting potential signal (yellow).
B Immuno-fluorescencent determination of K8's localization at the plasma membrane. 
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